Catalent cuts annual revenue forecast hurt by operational challenges

A

admin

Administrator
Jun 17, 2007
66,216
0
36
49
Canada
The contract drug manufacturer now sees its full-year revenue in the range of $4.25 billion to $4.35 billion compared with its prior forecast of $4.63 billion to $4.88 billion. Catalent manufactures drugs, vaccines and gene therapies at 55 different sites for major pharmaceutical companies, including Moderna Inc's COVID-19 vaccine, Novo Nordisk's weight-loss drug Wegovy and Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD).
 
You must log in or register to reply here.
Back
Top